Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach

Abstract

BackgroundSince pregnant women are severely underrepresented in clinical research, many take the position that the exclusion of pregnant women from research must be justified unless there are compelling “scientific reasons” for their exclusion. However, it is questionable whether this approach renders research with pregnant women fair. This paper analyzes and evaluates when research with pregnant women can be considered as fair and what constitutes scientific reasons for exclusion.MethodsConceptual ethical and methodological analysis and evaluation of fair inclusion.ResultsFair inclusion of pregnant women means (1) that pregnant women who are eligible are not excluded solely for being pregnant and (2) that the research interests of pregnant women are prioritized, meaning that they ought to receive substantially more attention. Fairness does not imply that pregnant women should be included in virtually every research project, as including only a few pregnant women in a population consisting only of women will not help to determine the effectiveness and safety of a treatment in pregnant women. Separate trials in pregnant women may be preferable once we assume, or know, that effects of interventions in pregnant women differ from the effects in other subpopulations, or when we assume, or know, that there are no differences. In the latter case, it may be preferable to conduct post-marketing studies or establish registries. If there is no conclusive evidence indicating either differences or equivalence of effects between pregnant and non-pregnant women, yet it seems unlikely that major differences or exact equivalence exist, the inclusion of pregnant women should be sufficient. Depending on the research question, this boils down to representativeness in terms of the proportion of pregnant and non-pregnant women, or to oversampling pregnant women.ConclusionsFair inclusion of pregnant women in research implies that separate trials in pregnant women should be promoted. Inclusion of pregnant women has to be realized at the earliest phases of the research process. In addition to researchers and research ethics committees, scientific advisory councils, funders, drug regulatory agencies, pharmaceutical companies, journal editors and others have a joint responsibility to further develop the evidence base for drug use in pregnant women.

Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects

“…Pregnant women are excluded from most drug trials . Pharmacokinetic studies involving pregnant women represent only 1.3% of all phase I trials registered through 2013 .…”

Enabling pregnant women and their physicians to make informed medication decisions using artificial intelligence

“…c illustrates how artificial intelligence or machine learning methods could be used to alert physicians and their patients at the appropriate time pertaining to specific details related to pregnant or nursing women Pregnant Women and Lactating Women (PRGLAC) wrote a report to the secretary of health and human services and Congress in September 2018, outlining strategies for identifying and addressing gaps in knowledge and research regarding drug use of pregnant and lactating women [49]. Because of this gap in scientific knowledge on the effects of treatments for the health needs of pregnant and lactating women, fair inclusion implies that a boost of research in this population is warranted [50]. While efforts in trial design are discussed [45], application of AI in this domain remains lacking.…”

Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy

“…Nonetheless, the fair inclusion of pregnant women in clinical trials necessitates that pregnant women should be included in the earliest phases of the research process when feasible in order to further develop the evidence base for drug use in this population. 77 Second, additional data are needed to understand whether increased cobicistat (Tybost) dosing during pregnancy will result in adequate boosting of CYP3Ametabolized antiretrovirals in future studies. Although cobicistat exposure is considerably decreased in pregnancy, higher-than-standard dosing (ie, >150 mg once daily) has not been studied during pregnancy.…”